ezetimibe + rosuvastatin (Shinpoong Pharma)

Ezerosu is a fixed-dose combination (FDC) medication containing ezetimibe and rosuvastatin, developed by Shin Poong Pharmaceutical for the management of hyperlipidemia. Ezetimibe acts as a selective cholesterol absorption inhibitor by targeting the Niemann-Pick C1-Like 1 (NPC1L1) transporter at the brush border of the small intestine, reducing the delivery of intestinal cholesterol to the liver. Rosuvastatin is a potent HMG-CoA reductase inhibitor (statin) that decreases endogenous cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface, enhancing the uptake and catabolism of LDL. By combining these two distinct mechanisms, Ezerosu provides a comprehensive approach to lowering low-density lipoprotein cholesterol (LDL-C) and improving overall lipid profiles. The product has been evaluated in various oral tablet formulations, including single-layer and double-layer configurations, to optimize stability and bioequivalence.

Brand names

Ezerosu

Other names

ezetimibe/rosuvastatinrosuvastatin + ezetimibe